WP
EWTX icon

Woodline Partners’s Edgewise Therapeutics EWTX Stock Holding History

Woodline Partners’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$7.07M Buy
224,290
+98
+0% +$2.83K 0.03% 591
2025
Q4 		$5.56M Buy
224,192
+2
+0% +$40 0.02% 605
2025
Q3 		$3.64M Sell
224,190
-872,673
-80% -$12.4M 0.02% 627
2025
Q2 		$14.4M Buy
1,096,863
+54
+0% +$779 0.08% 356
2025
Q1 		$24.1M Buy
1,096,809
+529,591
+93% +$13.9M 0.16% 190
2024
Q4 		$15.1M Buy
567,218
+39,379
+7% +$1.25M 0.1% 265
2024
Q3 		$14.1M Buy
527,839
+106,235
+25% +$2.11M 0.12% 240
2024
Q2 		$7.59M Buy
421,604
+16,472
+4% +$287K 0.07% 286
2024
Q1 		$7.39M Buy
405,132
+920
+0.2% +$14.6K 0.07% 313
2023
Q4 		$4.42M Buy
404,212
+44,119
+12% +$310K 0.05% 330
2023
Q3 		$2.06M Hold
360,093
– – 0.02% 398
2023
Q2 		$2.79M Hold
360,093
– – 0.03% 385
2023
Q1 		$2.4M Buy
360,093
+2
+0% +$19 0.03% 398
2022
Q4 		$3.22M Sell
360,091
-179,773
-33% -$1.69M 0.04% 386
2022
Q3 		$5.31M Sell
539,864
-231,933
-30% -$2.34M 0.07% 279
2022
Q2 		$6.14M Buy
771,797
+411,704
+114% +$3.11M 0.09% 230
2022
Q1 		$3.49M Sell
360,093
-42,756
-11% -$550K 0.06% 289
2021
Q4 		$6.16M Buy
402,849
+41,028
+11% +$738K 0.09% 259
2021
Q3 		$6.01M Buy
361,821
+7,332
+2% +$133K 0.1% 228
2021
Q2 		$7.56M Sell
354,489
-2,940
-0.8% -$80.4K 0.14% 174
2021
Q1 		$11.6M Buy
+357,429
New +$11.6M 0.26% 100

Other funds holding EWTX

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Woodline Partners's EWTX Position: Q1 2026 in Review

Woodline Partners increased its Edgewise Therapeutics (EWTX) stake by 0.04% in Q1 2026, buying an estimated $2.83K and bringing the position to 224,290 shares worth $7.07M. The position accounts for 0.03% of the portfolio, ranked #591.

Woodline Partners first reported a position in EWTX in Q1 2021 and has held it in 21 quarters since. The position peaked at $24.1M in Q1 2025. 214 funds tracked by Wall St. Rank hold EWTX as of Q1 2026.

  • Woodline Partners held 224,290 shares of Edgewise Therapeutics worth $7.07M as of Q1 2026.
  • Woodline Partners bought 98 Edgewise Therapeutics shares in Q1 2026, an estimated $2.83K.
  • Edgewise Therapeutics made up 0.03% of Woodline Partners's portfolio in Q1 2026, its #591 holding.
  • Woodline Partners first reported a position in Edgewise Therapeutics in Q1 2021 and has held it in 21 quarters since.
  • Woodline Partners's Edgewise Therapeutics position peaked at $24.1M in Q1 2025.
  • 214 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q1 2026.

Based on Woodline Partners's 13F filing for Q1 2026, filed 15 May 2026.